File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Impact of antiviral therapy on the survival outcome of patients after hepatectomy for hepatitis B-related hepatocellular carcinoma

TitleImpact of antiviral therapy on the survival outcome of patients after hepatectomy for hepatitis B-related hepatocellular carcinoma
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2010
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/1365182X.asp
Citation
The 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18-22 April 2010. In HPB, 2010, v. 12, suppl. S1, p. 52, abstract no. FP-101 How to Cite?
AbstractBACKGROUND: Although the therapeutic benefit of antiviral treatment in the management of chronic hepatitis B infection (HBV) is well-known, its impact on the survival outcome after hepatectomy for HBV-related hepatocellular carcinoma (HCC) remains unclear. AIM: To evaluate the impact of post-hepatectomy antiviral treatment on the prognosis of HBV-related HCC. METHODS: From September 2003 to December 2007, 42 patients were given Lamivudine (n = 39) or Entecavir (n = 4) after hepatectomy (i.e. treatment group) due to abnormal liver function. Their preoperative data, tumour characteristics and survival outcome were compared with 94 patients who did not receive any antiviral treatment after hepatectomy (i.e. control group). Univariate and multivariate analyses were performed to identify prognostic factors for survival. RESULTS: Patient demographics, preoperative liver function and tumour characteristics were comparable between the two study groups. The liver function reserve at the time of tumour recurrence in the treatment group was also comparable with the control group. There was no significant difference in tumour recurrence rate (47.6% vs. 65%, P = 0.28) and disease-free survival (69.8 vs. 9.2 months, P = 0.05) between the two study groups. Nonetheless, the overall survival was significantly improved in the treatment group (72.3 vs. 33.2 months, P = 0.005). Multivariate analysis identified use of antiviral treatment to be a prognostic factor for prolonged overall survival. Subgroup analysis stratified against tumour stage and portal vein status showed that the survival benefit of antiviral treatment was more pronounced in AJCC stage I/II tumours or HCCs without portal vein invasion. DISCUSSION: Antiviral therapy may improve the prognosis of HBV-related HCC by inhibition of hepatitis activity in the liver remnant. CONCLUSION: Antiviral treatment should be considered after hepatectomy for HBV-related HCC especially in early stage tumours.
DescriptionHPB - the official journal of the IHPBA
Free Papers Session
Persistent Identifierhttp://hdl.handle.net/10722/126922
ISSN
2015 Impact Factor: 2.918
2015 SCImago Journal Rankings: 1.586
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Aen_HK
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorYuen, WKen_HK
dc.contributor.authorChan, SCen_HK
dc.contributor.authorNg, KKC-
dc.contributor.authorPoon, RTP-
dc.contributor.authorLo, CM-
dc.contributor.authorFan, ST-
dc.date.accessioned2010-10-31T12:56:20Z-
dc.date.available2010-10-31T12:56:20Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18-22 April 2010. In HPB, 2010, v. 12, suppl. S1, p. 52, abstract no. FP-101en_HK
dc.identifier.issn1365-182X-
dc.identifier.urihttp://hdl.handle.net/10722/126922-
dc.descriptionHPB - the official journal of the IHPBA-
dc.descriptionFree Papers Session-
dc.description.abstractBACKGROUND: Although the therapeutic benefit of antiviral treatment in the management of chronic hepatitis B infection (HBV) is well-known, its impact on the survival outcome after hepatectomy for HBV-related hepatocellular carcinoma (HCC) remains unclear. AIM: To evaluate the impact of post-hepatectomy antiviral treatment on the prognosis of HBV-related HCC. METHODS: From September 2003 to December 2007, 42 patients were given Lamivudine (n = 39) or Entecavir (n = 4) after hepatectomy (i.e. treatment group) due to abnormal liver function. Their preoperative data, tumour characteristics and survival outcome were compared with 94 patients who did not receive any antiviral treatment after hepatectomy (i.e. control group). Univariate and multivariate analyses were performed to identify prognostic factors for survival. RESULTS: Patient demographics, preoperative liver function and tumour characteristics were comparable between the two study groups. The liver function reserve at the time of tumour recurrence in the treatment group was also comparable with the control group. There was no significant difference in tumour recurrence rate (47.6% vs. 65%, P = 0.28) and disease-free survival (69.8 vs. 9.2 months, P = 0.05) between the two study groups. Nonetheless, the overall survival was significantly improved in the treatment group (72.3 vs. 33.2 months, P = 0.005). Multivariate analysis identified use of antiviral treatment to be a prognostic factor for prolonged overall survival. Subgroup analysis stratified against tumour stage and portal vein status showed that the survival benefit of antiviral treatment was more pronounced in AJCC stage I/II tumours or HCCs without portal vein invasion. DISCUSSION: Antiviral therapy may improve the prognosis of HBV-related HCC by inhibition of hepatitis activity in the liver remnant. CONCLUSION: Antiviral treatment should be considered after hepatectomy for HBV-related HCC especially in early stage tumours.-
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/1365182X.asp-
dc.relation.ispartofHPB-
dc.rightsH P B: the official journal of the IHPBA. Copyright © Informa Healthcare.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleImpact of antiviral therapy on the survival outcome of patients after hepatectomy for hepatitis B-related hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1365-182X&volume=12&issue=suppl. S1&spage=52, abstract no. FP&epage=101&date=2010&atitle=Impact+of+antiviral+therapy+on+the+survival+outcome+of+patients+after+hepatectomy+for+hepatitis+B-related+hepatocellular+carcinoma-
dc.identifier.emailChan, A: albertchan@medscape.comen_HK
dc.identifier.emailChok, SH: kennethchok@yahoo.com.hken_HK
dc.identifier.emailYuen, WK: wkyuen@ha.org.hken_HK
dc.identifier.emailChan, SC: chanlsc@HKUCC.hku.hken_HK
dc.identifier.emailNg, KKC: kkcng@HKUCC.hku.hk-
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.authorityChan, A=rp00310en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.doi10.1111/j.1477-2574.2010.00165.x-
dc.identifier.pmid20495661-
dc.identifier.pmcidPMC2843160-
dc.identifier.hkuros172629en_HK
dc.identifier.volume12-
dc.identifier.issuesuppl. S1-
dc.identifier.spage52-
dc.identifier.epage101-
dc.description.otherThe 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18-22 April 2010. In HPB, 2010, v. 12, suppl. S1, p. 52, abstract no. FP-101-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats